Sitagliptin, marketed as Januvia, is an established anti-diabetic medication with a significant market presence. This study explores its potential to activate brown adipose tissue, thereby enhancing energy expenditure and reducing obesity-related metabolic disorders. If successful, this could expand Sitagliptin's therapeutic indications beyond glycemic control to include obesity management, tapping into the growing market for obesity treatments. The competitive landscape includes other GLP-1 receptor agonists and emerging therapies targeting BAT activation. Diligence is warranted regarding the regulatory pathways for these new indications and the potential for additional patent protections based on novel mechanisms of action.